Articles

Cure rates for children with cancer now exceed 80% in high-income countries (HIC), but several challenges remain. Read More ›

We have been hearing about the Affordable Care Act (ACA) for quite a while. However, many are still confused as to what this law is trying to accomplish and how it will benefit various populations of patients across the United States. Read More ›

In 2010, Congress passed (and the President signed into law) comprehensive healthcare legislation called the Patient Protection and Affordable Care Act (PPACA), or as it is more commonly known, the Affordable Care Act (ACA). Read More ›

In the spring of 2008, while I was finishing my oncology pharmacy residency training, I had the opportunity to spend a month in a prominent urban hospital very well known for its indigent patient population. Read More ›

The Affordable Care Act (ACA), officially called the Patient Protection and Affordable Care Act, which began implementation in March 2010 and will not be fully implemented until 2018, has impacted oncology care in both positive and negative ways. Read More ›

The second in a series of 4 articles describes the natural history of chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin lymphoma (NHL). As 2 indolent lymphocytic malignancies, they have a similar natural history of a slowly progressive illness that can have progressive cytopenias and/or lymphadenopathy that eventually may require therapy. Read More ›

This is the second article in a 4-part series on bendamustine. This article discusses the efficacy of bendamustine for patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) in the registration studies cited in the US product labeling Read More ›

Bendamustine is an active chemotherapy agent that has been studied for many years in a variety of malignancies; however, it has only been approved for use in the United States since 2008.1 Structurally, bendamustine shares similarities with both purine analogs and alkylating agents. Read More ›